These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9147586)

  • 1. The effect of incomplete knowledge of parameter values on single- and multiple-stage designs for logistic regression.
    Spears FM; Brown BW; Atkinson EN
    Biometrics; 1997 Mar; 53(1):1-10. PubMed ID: 9147586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose finding designs for continuous responses and binary utility.
    Fedorov VV; Wu Y
    J Biopharm Stat; 2007; 17(6):1085-96. PubMed ID: 18027218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-stage phase II trial design utilizing both primary and secondary endpoints.
    Lin X; Allred R; Andrews G
    Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating equations with incomplete categorical covariates in the Cox model.
    Lipsitz SR; Ibrahim JG
    Biometrics; 1998 Sep; 54(3):1002-13. PubMed ID: 9750248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixture models for continuous data in dose-response studies when some animals are unaffected by treatment.
    Boos DD; Brownie C
    Biometrics; 1991 Dec; 47(4):1489-504. PubMed ID: 1786327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal and repeated cross-sectional cluster-randomization designs using mixed effects regression for binary outcomes: bias and coverage of frequentist and Bayesian methods.
    Localio AR; Berlin JA; Have TR
    Stat Med; 2006 Aug; 25(16):2720-36. PubMed ID: 16345043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian semiparametric modeling for matched case-control studies with multiple disease states.
    Sinha S; Mukherjee B; Ghosh M
    Biometrics; 2004 Mar; 60(1):41-9. PubMed ID: 15032772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive design and estimation in randomized clinical trials with correlated observations.
    Yin G; Shen Y
    Biometrics; 2005 Jun; 61(2):362-9. PubMed ID: 16011682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the efficiency of two-stage response-adaptive designs.
    Dette H; Bornkamp B; Bretz F
    Stat Med; 2013 May; 32(10):1646-60. PubMed ID: 22865374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian approach to a logistic regression model with incomplete information.
    Choi T; Schervish MJ; Schmitt KA; Small MJ
    Biometrics; 2008 Jun; 64(2):424-30. PubMed ID: 17764482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Planning a dose-response study with subject-specific doses.
    Gönen M
    Stat Med; 2005 Sep; 24(17):2613-23. PubMed ID: 15977297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity to initial values in full non-parametric maximum-likelihood estimation of the two-parameter logistic model.
    Nader IW; Tran US; Formann AK
    Br J Math Stat Psychol; 2011 May; 64(Pt 2):320-36. PubMed ID: 21492136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian design and analysis of two x two factorial clinical trials.
    Simon R; Freedman LS
    Biometrics; 1997 Jun; 53(2):456-64. PubMed ID: 9192445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
    Bekele BN; Shen Y
    Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal spending functions for asymmetric group sequential designs.
    Anderson KM
    Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-stage designs for the logistic regression model in single-agent bioassays.
    Myers WR; Myers RH; Carter WH; White KL
    J Biopharm Stat; 1996 Jul; 6(3):283-301. PubMed ID: 8854233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method.
    Legedza AT; Ibrahim JG
    Stat Med; 2001 Mar; 20(6):867-82. PubMed ID: 11252009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling clinical trials in heterogeneous samples.
    Liu W; Zhao W; Shaffer ML; Icitovic N; Chase GA
    Stat Med; 2005 Sep; 24(18):2765-75. PubMed ID: 16007572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.